Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation : phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database
Giner-Soriano, Maria (Universitat Autònoma de Barcelona)
Vedia Urgell, Cristina (Universitat Autònoma de Barcelona)
Roso-Llorach, Albert (Universitat Autònoma de Barcelona)
Morros, Rosa (Universitat Autònoma de Barcelona)
Capellà, Dolors (Universitat de Girona. Departament de Ciències Mèdiques)
Castells, Xavier (Universitat de Girona. Departament de Ciències Mèdiques)
Ferreira-Gonzalez, Ignacio (Hospital Universitari Vall d'Hebron)
Troncoso Mariño, Amelia (Hospital Universitari Vall d'Hebron)
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron)
Elorza, Josep Mª (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Casajuana Closas, Marc (Universitat Autònoma de Barcelona)
Bolíbar, Bonaventura (Universitat Autònoma de Barcelona)
Violán, Concepció (Universitat Autònoma de Barcelona)

Date:	2016
Abstract:	Atrial fibrillation is the most common arrhythmia. Its management aims to reduce symptoms and to prevent complications through rate and rhythm control, management of concomitant cardiac diseases and prevention of related complications, mainly stroke. The main objective of Effectiveness, Safety and Costs in Atrial Fibrillation (ESC-FA) study is to analyse the drugs used for the management of the disease in real-use conditions, particularly the antithrombotic agents for stroke prevention. The aim of this work is to present the study protocol of phase I of the ESC-FA study and the baseline characteristics of newly diagnosed patients with atrial fibrillation in Catalonia, Spain. The data source is System for the Improvement of Research in Primary Care (SIDIAP) database. The population included are all patients with non-valvular atrial fibrillation diagnosis registered in the electronic health records during 2007-2012. A total of 22 585 patients with non-valvular atrial fibrillation were included in the baseline description. Their mean age was 72. 8 years and 51. 6% were men. The most commonly prescribed antithrombotics were vitamin K antagonists (40. 1% of patients) and platelet aggregation inhibitors (32. 9%); 25. 3% had not been prescribed antithrombotic treatment. Age, gender, comorbidities and co-medication at baseline were similar to those reported for previous studies. The next phase in the ESC-FA study will involve assessing the effectiveness and safety of antithrombotic treatments, analysing stroke events and bleeding episodes' rates in our patients (rest of phase I), describing the current management of the disease and its costs in our setting, and assessing how the introduction of new oral anticoagulants changes the stroke prevention in non-valvular atrial fibrillation.
Note:	Altres ajuts: MSSSI/EC11-251
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Atrial fibrillation ; Electronic health records ; Platelet aggregation inhibitors
Published in:	BMJ open, Vol. 6, issue 1 (Jan. 2016) , art. e010144, ISSN 2044-6055

DOI: 10.1136/bmjopen-2015-010144
PMID: 26823179

11 p, 1.4 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles